To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …

Tissue microarray (TMA) technology allows a massive acceleration of studies correlating
molecular in situ findings with clinico‐pathological information. In this technique, cylindrical …

… Lukas Bubendorf (interrelatedness of TMB and other immune-oncology/genomic biomarkers);
Dr. Solange Peters (current status and controversies); Dr. Ahmet Zehir (review of technical …

… 3 Summary of results obtained (l ER/p53* with the tumor tissue microarray technology in
the characterization of … Zhang, L. et al. Gene expression profiles in normal and cancer cells. …

The prognosis of prostate cancer is mainly determined by thepresence or absence of metastases.
Nevertheless, the metastasic pathways in prostate cancer are not entirely understood. …

Background Many cases of hereditary breast cancer are due to mutations in either the
BRCA1 or the BRCA2 gene. The histopathological changes in these cancers are often …

… Bubendorf reports grants and personal fees from Roche and Merck Sharp and Dohme and
personal fees from Bristol-Myers Squibb and AstraZeneca during the conduct of the study. Dr. …

Prostate cancer development and progression is driven by the accumulation of genetic
changes, the nature of which remains incompletely understood. To facilitate high-throughput …

Epithelial cell adhesion molecule (Ep-CAM; CD326) is used as a target by many immunotherapeutic
approaches, but little data are available about Ep-CAM expression in major human …

To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …